Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × sargramostim × Clear all

Phase

Status

Sponsor Class

OTHER 10 NIH 4 NETWORK 1 INDUSTRY 1 INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 5 Glioblastoma 3 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Glioma 1 Brain Neoplasms 1 Advanced Ovarian Cancer 1 Advanced Cancer 1

Interventions

Prednisone 81 Docetaxel 64 enzalutamide 59 Abiraterone Acetate 54 Leuprolide 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 40 abiraterone 27 apalutamide 25 bicalutamide 22 pembrolizumab 20 radium Ra 223 dichloride 19 Zoledronic Acid 19 Prednisolone 19 Goserelin 19 darolutamide 18 Triptorelin Pamoate 13 sipuleucel-T 12 luprolide acetate gel depot 12 Androgen Antagonists 12 cabazitaxel 11 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Ipilimumab 9 orteronel 7 Standard of Care 7 Mitoxantrone 7 Lutetium-177 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01784913 2024-12-16

UV1/hTERT2012P

Ultimovacs ASA

Phase 1/2 Completed

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡